NCT00618319View on ClinicalTrials.gov

An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST)

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions
GIST
Interventions
DRUG

BIIB021

Dose, schedule, and duration specified in protocol

Trial Locations (3)

90404

Research Site, Santa Monica

Unknown

Reseach Facility, Encinitas

Reseach Facility, San Antonio

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY